Innoviva (INVA)
(Delayed Data from NSDQ)
$19.83 USD
+0.09 (0.46%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $19.84 +0.01 (0.05%) 7:22 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.83 USD
+0.09 (0.46%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $19.84 +0.01 (0.05%) 7:22 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Innoviva (INVA) Misses Q2 Earnings Estimates
by Zacks Equity Research
Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.78% and 0.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
by Zacks Equity Research
Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
by Zacks Equity Research
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellus Health (BLU) and Innoviva (INVA) have performed compared to their sector so far this year.
Earnings Preview: Innoviva (INVA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Tops Q1 Earnings Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.69% and 1.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition
by Zacks Equity Research
Pfizer (PFE) inks an agreement to acquire ReViral for up to $525 million, which will add the latter's respiratory syncytial virus therapeutic candidates to its portfolio.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group
by Zacks Equity Research
Meridian Bioscience, Innoviva, OP Bancorp and United Fire Group are part of Screen of the Week article.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
by Zacks Equity Research
The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.
Bet on These 4 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), OP Bancorp (OPBK) and United Fire Group (UFCS) are well poised to gain.
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.
J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents
by Zacks Equity Research
The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
by Zacks Equity Research
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer
by Zacks Equity Research
Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.
Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer
by Zacks Equity Research
The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.
Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study
by Zacks Equity Research
Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
by Zacks Equity Research
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Henry Schein (HSIC) and Innoviva (INVA) have performed compared to their sector so far this year.
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B
by Zacks Equity Research
Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.
Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU
by Zacks Equity Research
Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
by Zacks Equity Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.